Result of General Meeting

RNS Number : 5455P

IXICO plc

29 May 2018

 

29 May 2018

IXICO plc

("IXICO" or the "Company")

Result of General Meeting

Further to the announcement on 3 May 2018 in relation to the placing ("Placing") of new ordinary shares ("Placing Shares") in the Company to raise £5.5 million and the despatch of a related shareholder circular, IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, is pleased to announce that all resolutions proposed at the General Meeting of the Company held earlier today were duly passed.

Total voting rights

As a result, the Placing has become unconditional other than in respect of admission of the Placing Shares to trading on AIM. Application has been made for admission to trading on AIM of 19,642,856 Placing Shares. Admission of the Placing Shares on AIM is expected to become effective at 8.00 a.m. on 30 May 2018, following which there will be in total 46,761,986 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Edward Mansfield / Anita Ghanekar / Daniel Bush	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: [phone]

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

 

END

 

 

ROMLLFILEEIAFIT